The Enhanced liver fibrosis score is associated with clinical outcomes and disease progression in patients with chronic liver disease
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Background and Aims: Current tools for risk stratification of chronic liver disease subjects are limited. We aimed to determine whether the serum‐based ELF (Enhanced Liver Fibrosis) test predicted liver‐related clinical outcomes, or progression to advanced liver disease, and to compare the performance of ELF to liver biopsy and non‐invasive algorithms. Methods: Three hundred patients with ELF scores assayed at the time of liver biopsy were followed up (median 6.1 years) for liver‐related clinical outcomes (n = 16) and clear evidence of progression to advanced fibrosis (n = 18), by review of medical records and clinical data. Results: Fourteen of 73 (19.2%) patients with ELF score indicative of advanced fibrosis (≥9.8, the manufacturer's cut‐off) had a liver‐related clinical outcome, compared to only two of 227 (<1%) patients with ELF score <9.8. In contrast, the simple scores APRI and FIB‐4 would only have predicted subsequent decompensation in six and four patients respectively. A unit increase in ELF score was associated with a 2.53‐fold increased risk of a liver‐related event (adjusted for age and stage of fibrosis). In patients without advanced fibrosis on biopsy at recruitment, 55% (10/18) with an ELF score ≥9.8 showed clear evidence of progression to advanced fibrosis (after an average 6 years), whereas only 3.5% of those with an ELF score <9.8 (8/207) progressed (average 14 years). In these subjects, a unit increase in ELF score was associated with a 4.34‐fold increased risk of progression. Conclusions: The ELF score is a valuable tool for risk stratification of patients with chronic liver disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lozano, R., Naghavi, M., Foreman, K., Lim, S., Shibuya, K., Aboyans, V., Abraham, J., Adair, T., Aggarwal, R., Ahn, S. Y., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61728-0 · Cited by 14,070
Sterling, R. K., Lissen, E., Clumeck, N., Sola, R., Correa, M. C., Montaner, J., S. Sulkowski, M., Torriani, F. J., Dieterich, D. T., Thomas, D. L., et al. (2006) · Hepatology · doi:10.1002/hep.21178 · Cited by 5,021 · cited 2×
“25 (10), consensus cut-offs for significant and advanced fibrosis, respectively, compared to 14 patients with an ELF score ≥9.”
MethodAngulo, P., Bugianesi, E., Bjornsson, E. S., Charatcharoenwitthaya, P., Mills, P. R., Barrera, F., Haflidadottir, S., Day, C. P., & George, J. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.06.057 · Cited by 502 · cited 1×
“This is in contrast to a small number of studies showing that serum markers including APRI and FIB-4 predicted shorter survival times in patients with chronic HCV (n = 1457) (21); higher risk for liver-related events and overall mortality in NAFLD patients (n = 320) (22); and higher prognostic value for FIB-4 than liv…”
ResultUnderestimation of liver‐related mortality in the United States
Asrani, S. K., Larson, J. J., Yawn, B., Therneau, T. M., & Kim, W. R. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.04.005 · Cited by 311
Cited by
Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine
Fujiwara, N., Friedman, S. L., Goossens, N., & Hoshida, Y. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2017.09.016 · Cited by 659
Harrison, S. A., Ruane, P. J., Freilich, B. L., Neff, G., Patil, R., Behling, C. A., Hu, C., Fong, E., de Temple, B., Tillman, E. J., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01425-3 · Cited by 368
Rinella, M. E., Dufour, J.-F., Anstee, Q. M., Goodman, Z., Younossi, Z., Harrison, S. A., Loomba, R., Sanyal, A. J., Bonacci, M., Trylesinski, A., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.10.029 · Cited by 164
de Vries, E. M. G., Färkkilä, M., Milkiewicz, P., Hov, J. R., Eksteen, B., Thorburn, D., Chazouillères, O., Pares, A., Nygård, S., Gilja, O. H., et al. (2017) · Liver International · doi:10.1111/liv.13402 · Cited by 83
“and FIB-4 did not identify patients with higher risk of developing liver related events while ELF test did.[16] The most widely used prognostic model in PSC research is the Mayo Risk model; however, this model notably failed to predict adverse outcomes in high-dose ursodeoxycholic acid studies.”
Method
Metadata
- Authors
- Irvine, K. M., Wockner, L. F., Shanker, M., Fagan, K. J., Horsfall, L. U., Fletcher, L. M., Ungerer, J. P. J., Pretorius, C. J., Miller, G. C., Clouston, A. D., Lampe, G., & Powell, E. E.
- Venue
- Liver International
- Publisher
- Wiley
- Published
- 2015-08-28
- Volume
- 36
- Issue
- 3
- Pages
- 370-377
- ISSN
- 0106-9543 (ISSN-L)
- 1478-3223
- 1478-3231
- OpenAlex
- W1889367418
- Cited by
- 86
- References
- 4
- FWCI
- 3.90
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Enhanced liver fibrosis score is associated with clinical outcomes and disease progression in patients with chronic liver disease. https://app.cochat.ai/papers/10.1111/liv.12896
- The paper
- Irvine, K. M., Wockner, L. F., Shanker, M., Fagan, K. J., Horsfall, L. U., Fletcher, L. M., Ungerer, J. P. J., Pretorius, C. J., Miller, G. C., Clouston, A. D., Lampe, G., & Powell, E. E. (2016). The Enhanced liver fibrosis score is associated with clinical outcomes and disease progression in patients with chronic liver disease. Liver International. https://doi.org/10.1111/liv.12896
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.